We are live on ! Find out more
CLSD

Clearside Biomedical
CLSD

Delisted

CLSD was delisted on the 28th of November, 2025.

Back to rankings

54 hedge funds and large institutions have $86.3M invested in Clearside Biomedical in 2017 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 15 increasing their positions, 16 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 6

8% more funds holding

Funds holding: 50 → 54 (+4)

0.2% less ownership

Funds ownership: 3.44% → 3.24% (-0.2%)

6% less repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 16

24% less capital invested

Capital invested by funds: $114M → $86.3M (-$27.8M)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
54
Holders Change
+4
Holders Change %
+8%
% of All Funds
1.22%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
10
Increased
15
Reduced
16
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SFM
Sphera Funds Management
Israel
+$1.07M
2
Russell Investments Group
Russell Investments Group
United Kingdom
+$813K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$372K
4
HIM
Hillhouse Investment Management
Cayman Islands
+$316K
5
TI
Trexquant Investment
Connecticut
+$257K

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$3.2M
2
BlackRock
BlackRock
New York
-$2.69M
3
Wellington Management Group
Wellington Management Group
Massachusetts
-$1.32M
4
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$658K
5
GIP
Granite Investment Partners
California
-$533K
Name Holding Trade Value Shares
Change 		Change in
Stake
Wellington Management Group
1
Wellington Management Group
Massachusetts
$19.6M -$1.32M -12,265 -6%
CAM
2
Cormorant Asset Management
Massachusetts
$13.6M – – –
BlackRock
3
BlackRock
New York
$6.88M -$2.69M -25,041 -28%
HIM
4
Hillhouse Investment Management
Cayman Islands
$6.61M +$316K +2,947 +5%
RSCM
5
Rock Springs Capital Management
Maryland
$6.54M – – –
Vanguard Group
6
Vanguard Group
Pennsylvania
$5.41M +$372K +3,464 +7%
PA
7
Perceptive Advisors
New York
$4.34M – – –
Fidelity Investments
8
Fidelity Investments
Massachusetts
$3.74M -$3.2M -29,783 -46%
SFM
9
Sphera Funds Management
Israel
$3.15M +$1.07M +10,000 +50%
First Manhattan
10
First Manhattan
New York
$2.45M – – –
State Street
11
State Street
Massachusetts
$2.02M +$141K +1,312 +7%
Northern Trust
12
Northern Trust
Illinois
$1.57M -$16.3K -152 -1%
MWNA
13
Marshall Wace North America
New York
$1.51M – – –
Geode Capital Management
14
Geode Capital Management
Massachusetts
$908K +$26.8K +250 +3%
Russell Investments Group
15
Russell Investments Group
United Kingdom
$794K +$813K +7,571 New
BCM
16
Bridgeway Capital Management
Texas
$785K – – –
AIC
17
AWM Investment Company
New York
$770K +$55.6K +518 +8%
Bank of New York Mellon
18
Bank of New York Mellon
New York
$636K -$2.04K -19 -0.3%
KCM
19
Kornitzer Capital Management
Kansas
$525K – – –
TCIM
20
TIAA CREF Investment Management
New York
$406K +$47.1K +439 +13%
Morgan Stanley
21
Morgan Stanley
New York
$364K +$39K +363 +12%
WS
22
Wedbush Securities
California
$342K +$140K +1,300 +67%
Goldman Sachs
23
Goldman Sachs
New York
$332K +$76.7K +714 +29%
Deutsche Bank
24
Deutsche Bank
Germany
$331K +$86K +801 +34%
TA
25
Teachers Advisors
New York
$281K +$24.6K +229 +9%
1
2 3

CLSD Hedge Fund Activity: Q4 2017 in Review

54 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Clearside Biomedical (CLSD) for Q4 2017, worth a combined $86.3M — down 24% from $114M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new CLSD positions and 6 closed out — a net gain of 4 holders — while 15 added to existing stakes and 16 trimmed.

The largest buyer was Sphera Funds Management, adding an estimated $1.07M. The largest seller was Fidelity Investments, cutting an estimated $3.2M.

  • 54 institutional investors held Clearside Biomedical (CLSD) as of Q4 2017, up from 50 in Q3 2017.
  • Funds reported $86.3M of Clearside Biomedical stock for Q4 2017, down 24% quarter-over-quarter.
  • 10 funds opened new Clearside Biomedical positions in Q4 2017 and 6 closed out, a net change of +4 holders.
  • The largest Clearside Biomedical buyer in Q4 2017 was Sphera Funds Management, an estimated $1.07M added.
  • The largest Clearside Biomedical seller in Q4 2017 was Fidelity Investments, an estimated $3.2M sold.

Based on aggregated 13F filings for Q4 2017.